

FISH &amp; RICHARDSON P.C.

SUBSTITUTE PTOL-413A (OS-OS)  
ATTORNEY'S DOCKET NO.: 10287-051002**Applicant Initiated Interview Request Form**

Application No. : 09/822,682

First Named Applicant:

Michael Detmar

Examiner: Misook Yu

Art unit: 1642

Status of Application:

**Tentative Participants:**

(1) Louis Myers

(2) Leda Trivinos

(3) Margo Furman

(4) \_\_\_\_\_

Proposed Date of Interview: July 8, 2003

Proposed Time: 1:30 PM

**Type of Interview Requested:**(1) ☒ Telephonic(2) ☐ Personal(3) ☐ Video ConferenceExhibit To Be Shown or Demonstrated: ☐ YES☒ NO

if yes, provide brief description: \_\_\_\_\_

**Issues To Be Discussed**

Issues (Rej., Obj., etc)	Claims Fig. #s	Prior Art	Discussed	Agreed	Not Agreed
(1) <u>Enablement</u>	<u>54-85</u>	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(2) <u>Written Description</u>	<u>81-82</u>	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(3) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(4) _____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☒ Continuation Sheet Attached**Brief Description of Arguments to be Presented:**We would like to discuss the Examiner's enablement and written description rejections in view of the specification and other data provided by the Applicants.

An interview was conducted on the above-identified application on \_\_\_\_\_.

**NOTE:**

This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP § 713.01).

This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible.

(Applicant/Applicant's Representative Signature) \_\_\_\_\_

(Examiner/SPE Signature) \_\_\_\_\_

Proposed New Claim

86. (Proposed New Claim) A method of treating a subject having a disorder characterized by unwanted cell proliferation, the method comprising:

identifying a subject having a disorder characterized by unwanted cell proliferation; and

administering to the subject a cell expressing a TSP-2 comprising an amino acid sequence identical to the sequence of SEQ ID NO:2, or a functional fragment thereof, capable of inhibiting endothelial cell migration, wherein the fragment comprises at least 10 contiguous amino acids of either a procollagen domain of TSP-2, or a type I repeat of TSP-2.